Try our corporate solution for free!
(212) 419-8286
hadley.ward@statista.com

Projected most valuable R&D projects based on net present value 2019

This statistic displays the top pharmaceutical R&D projects based on net present value, as of November 2019. According to the source, the top R&D project was Eli Lilly's diabetes drug Tirzepatide with a net present value of 11.7 billion U.S. dollars at that time. Drugs targeting cancer and autoimmune conditions are most present among the top projects.

Selected top pharmaceutical R&D projects based on net present value (NPV) as of November 2019 (in billion U.S. dollars)*

Loading statistic...
You need to log in to download this statistic
Register for free
Already a member?
Log in
Show detailed source information?
Register for free
Already a member?
Log in
Sources

Release date

December 2019

Region

Worldwide

Survey time period

as of November 2019

Supplementary notes

* Excludes products forecast to launch next year. NPV based on sellside consensus sales. Forecasts for SAGE-217 collated before the failure of the phase III Mountain study.

Statista Accounts: Access All Statistics. Starting from $468 / Year
Basic Account
Get to know the platform

You only have access to basic statistics.

Single Account
The ideal entry-level account for individual users
  • Instant access to 1m statistics
  • Download in XLS, PDF & PNG format
  • Detailed references
$59 $39 / Month *
in the first 12 months
Corporate Account
Full access

Corporate solution including all features.

* Prices do not include sales tax.

Statistics on "Amgen"

Further Content: You might find this interesting as well

Statista Accounts: Access All Statistics. Starting from $468 / Year
Learn more about how Statista can support your business.